A couple of posts from ihub, Fletch falconer66a

New Post Public Reply Private Reply Replies (1) Message Board
fletch Drano #863
630
A couple of posts from ihub,
Fletch

falconer66a Monday, 08/20/18 12:55:23 PM
Re: lqmike post# 163245 0
Post #
163251
of 163257
Life-long Anavex Dosing?

If Anavex 2-73 (or any of the other Anavex molecules) proves to be profoundly prophylactic (disease-preventing) — as I think will be the case — the best age to begin dosing will need to be determined. Age 50? Seems reasonable to prevent Alzheimer’s. Not many show symptoms before that age. But, yes, other central nervous system diseases can have earlier onsets.

Several questions will have to be answered. Big one is this. Just what diseases and conditions might Anavex sigma-1 receptor agonists prevent when administered early enough?

What if it turns out that a host of human diseases result from, or are allowed to happen because intrinsic, natural sigma-1 receptor agonists fail at various stages of development or aging?

Now, this is a universal, uncontested biological fact. Virtually all chemical reactions in organisms are controlled, mediated, and promoted by precisely-formed, folded enzyme proteins. Mis-fold or distort an enzyme, and biochemical processes are disrupted. Many neurotoxin poisons of snakes and other organisms work by distorting enzyme shapes. They can no longer control or promote normal chemical reactions; death or injury ensue. A number of genetic diseases are known to occur when essential enzymes are improperly, incompletely, or absently produced. Most often, that happens because of a genetic defect; the nucleotide sequence of the controlling gene is out of order.

So, what if it’s discovered that Anavex sigma-1 receptor agonists restore normalized enzyme production in a host of cell types, at a variety of developmental stages, even embryonic? Too lengthy for me to deliberate the matter here, but for me, examination of all of the known murine study data, and the hints on the matter revealed by the Anavex pipeline drugs and the diseases they may treat, I am lead to believe that the roles Anavex sigma-1 receptor agonists might play in preventing just a host of developmental diseases and conditions, even in the uterus, could be (to use a phrase) “an iceberg.”

falconer66a Monday, 08/20/18 12:11:31 PM
Re: plexrec post# 163238 0
Post #
163243
of 163257
The Inflammation Factor

Yes, the “waste proteins” of Alzheimer’s, the beta-amyloids and tau tangles, are decidedly inflammatory, as proven in murine studies. Inflammation of nerves and nerve tissues is always problematic. When inflammation is well-controlled and properly restrained, it initiates and modulates appropriate immunological attacks on extrinsic pathogens, bacteria in particular; in some cases viruses. Well and good.

But inflammation can call out too many immunological defense troops (empowered leucocytes) who then fail to discriminate between invading, infecting pathogens from normal body cells and tissues. Not only are pathogens “controlled,” normal cells and tissues are attacked and slain. One needn’t know much biology to imagine what results when nerves are so attacked.

The author states, “It seems that if given early enough ANAVEX 2-73 can stop or even reverse progress of the disease.”

If Anavex 2-73 can cause neurons to accurately create proteins, by allowing endoplasmic reticula to function normally, enzyme proteins will be folded into their proper, functioning shapes, thereby creating normalized, healthful chemistries within the neuron. No disease onset.

Personally, I’ve contended this myself a number of times. Administering Anavex 2-73 after beta amyloid and tau wastes have profusely accumulated and induced neuron-destroying inflammation may not be useful. The wastes have accumulated, induced inflammation, and affected neurons cannot be salvaged. But start the treatment early, before waste proteins have much accumulated, and the normalized protein enzymes from the Anavex-restored endoplasmic reticula will maintain, even restore neuron function.

Why wait to treat Alzheimer’s with Anavex 2-73 until severe, irreversible damage to neurons and nerves has occurred? Treat at the very first signs of Alzheimer’s, before irrevocable damage has occurred, before waste proteins have accumulated to any degree.

With 300 people taking Anavex 2-73 in the upcoming trial, a computer’s plotting of outcomes should reveal if this scenario is accurate. If it is, those taking the drug at earlier stages of the disease will have better results. Those at more advanced stages will have reduced positive outcomes.

I’ve also contended that eventually Anavex 2-73 may be universally prescribed to virtually every one, at some yet to be determined age, say, age 50. With that, any of the central nervous system diseases (or others) can be prevented from developing. Treated and prevented at the start, before any irrevocable, chronic damage has been done.

When you were ten, your mother in winter used to say, “Better put on your coat. We don’t want you to catch a cold.” Will physicians sometime be saying to their mid-aged patients, “Well, I see you are approaching your 50th birthday. Time for you to start taking an Anavex pill each day. We don’t want you to develop any of those horrible diseases people used to get?”

https://investorshub.advfn.com/Anavex-Life-Sc...VXL-11474/

Anavex Life Sciences Corp. (AVXL) Stock Research Links

AVXL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Davos Healthcare Aims to Revolutionize Hospital Ratings

Updated Category News Views 2

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Continue Reading
Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Updated Category News Views 4

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

Continue Reading
K-Beauty Takes Front Stage at Target Beauty Studio

Updated Category News Views 3

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Continue Reading
FutureVault's AI Agents: Transforming Financial Workflows

Updated Category News Views 4

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Continue Reading
Anecdotes by Artists Brings Raw Scent Stories to Sephora

Updated Category News Views 2

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 7

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 3

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading
HTX's Strategic Moves in Pakistan: A Crypto Frontier

Updated Category News Views 4

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Cracking the Code of America's Delivery Addiction

Updated Category News Views 4

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Continue Reading

Top 5 Most Recently Viewed Articles

EMP Metals Unveils Enhanced Resource Estimate for Lithium Projects

Updated Category News Views 96

EMP Metals Reports Updated Resource Estimate EMP Metals Corp. (CSE: EMPS, OTCQB: EMPPF) is thrilled to share an updated Technical Report detailing the resource estimates for its Viewfield and Mansur lithium brine projects. This comprehensive report showcases a remarkable increase in the total resource, significantly boosting both the indicated and inferred lithium...

Continue Reading
Veriff Celebrates Trust Awards for Outstanding Innovators

Updated Category News Views 328

Veriff Celebrates Trust Awards for Outstanding Innovators Today, Veriff, a leader in AI-driven identity verification, proudly recognized the first annual Veriff Trust Awards winners. This celebration highlights companies and individuals making significant strides towards enhancing trust in the online space and contributing to a safer internet. Rising Threats in Online...

Continue Reading
BitFuFu Achieves Significant Growth in Bitcoin Mining Sector

Updated Category News Views 187

BitFuFu Reports Robust Financial Results for Q2 2025 BitFuFu Inc. (NASDAQ: FUFU), a leading innovator in Bitcoin mining services, recently shared its impressive financial performance for the second quarter of 2025, recording significant growth in revenues and net income. Financial Highlights from Q2 2025 For the quarter ended June 30, 2025, BitFuFu achieved year-over-year...

Continue Reading
Pivot Bio Welcomes Melih Keyman to Board, Enhancing Expertise

Updated Category News Views 256

Pivot Bio Strengthens Leadership with New Board Member New director brings rich agriculture and fertilizer experience to the forefront of innovation Pivot Bio, recognized for its groundbreaking advancements in the agricultural technology sector, has appointed Melih Keyman to its Board of Directors. This strategic move is expected to bolster the company's growth and...

Continue Reading
Midland Exploration Unveils Promising Mineral Discoveries

Updated Category News Views 151

Significant Discoveries at the Saruman Project Midland Exploration Inc. (TSX-V: MD) is excited to announce the identification of copper-gold-molybdenum-silver occurrences on its Saruman project. This project, located in a region characterized by potential mineral wealth, consists of 121 claims covering an area of 64 square kilometers, which Midland acquired through map...

Continue Reading